Respiratory Syncytial Virus News and Research

RSS

Southampton scientists set to analyse investments into infectious disease research

Scientists at the University of Southampton are set to analyse research investments into infectious disease research, particularly pneumonia and maternal and neonatal infections, after receiving over £370,000 in funding from the Bill & Melinda Gates Foundation.

23 Jul 2015

Harvard Medical School scientists reveal structure of vesicular stomatitis virus protein

Viruses need us. In order to multiply, viruses have to invade a host cell and copy their genetic information. To do so, viruses encode their own replication machinery or components that subvert the host replication machinery to their advantage.

3 Jul 2015

Vaccines - a needle-free future? An interview with Thomas Johnston and Dr. Kees Leenhouts, Mucosis

Scientists recognize that 90% of pathogens actually enter the body through the mucosa and secondly, we have evolved a mucosal defense system that can be used to defend against disease...

1 Jun 2015

Gas naturally produced within our bodies reduces severity of RSV infection, UTMB study finds

A new study from the University of Texas Medical Branch at Galveston is the first to show that hydrogen sulfide, a gas produced naturally within our bodies, reduces the severity of respiratory syncytial virus, or RSV.

28 Apr 2015

Loyola otolaryngologist offers tips to identify, treat ear infection in children

Earaches in babies are not uncommon. But a baby's inability to communicate symptoms can leave most parents feeling helpless. According to the American Academy of Pediatrics, three-fourths of babies will get at least one ear infection before the age of one.

8 Apr 2015

Study: Gene variant, urban environment increase risk of severe disease in children infected with RSV

A particular genetic mutation combined with an urban environment increases the risk of severe disease in children infected with respiratory syncytial virus (RSV), an international team of investigators has found.

8 Apr 2015

RSV infection rate on the rise among young children

Children with Respiratory Syncytial Virus (RSV), a common virus that infects the lungs and breathing passageways, has been on the rise across the nation for the last several years. Though it may only produce minor cold symptoms in adults, it can lead to serious illness in young children and those with compromised immune systems.

30 Mar 2015

Study reveals causes of community-acquired pneumonia in children

With the chill of winter comes a spike in community-acquired pneumonia (CAP), which spreads more easily as people retreat indoors and come into close contact. The lung infection triggers persistent coughing, chest pain, fever, and difficulty breathing, and is particularly hard on the very young and the very old. In fact, pneumonia is the leading cause of hospitalization among U.S. children, with estimated medical costs of $1 billion annually.

26 Feb 2015

Study points respiratory viruses as the most common cause of childhood pneumonia

Respiratory viruses, not bacterial infections, are the most commonly detected causes of community-acquired pneumonia in children, according to new research released Feb. 26 in the New England Journal of Medicine.

26 Feb 2015

Mobile diagnosis device to help reduce unnecessary antibiotics prescribing

New biosensor-based technology could help to reduce the over-prescribing of antibiotics by giving GPs and other frontline healthcare staff an accurate and fast method of identifying the nature of infectious diseases.

15 Jan 2015

Focus Diagnostics' Simplexa Flu A/B & RSV Direct Kit receive FDA clearance

As the 2014-2015 flu season begins, Focus Diagnostics, the products business of Quest Diagnostics, today announced that its Simplexa Flu A/B & RSV Direct Kit has received FDA clearance for eight additional influenza strains. These strains may pose significant potential health risks and may be circulating this winter.

From Quest Diagnostics 9 Dec 2014

Infant mortality rates for RSV much lower than previously thought

It's a virus that has long been characterized as dangerous and even deadly, but new research shows infant deaths from respiratory syncytial virus (RSV) are actually quite uncommon in the 21st century.

9 Dec 2014

Johnson & Johnson completes acquisition of Alios BioPharma

Johnson & Johnson today announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash.

8 Nov 2014

Scientists develop promising vaccination strategy to counteract RSV infection

Respiratory Syncytial Virus causes severe respiratory tract infections and worldwide claims the lives of 160,000 children each year. Scientists at VIB and Ghent University have succeeded in developing a promising vaccination strategy to counteract this common virus infection.

17 Oct 2014

Promising vaccination strategy to counteract RSV

16 Oct 2014

Mymetics' innovative HIV vaccine candidate to enter new preclinical trial

Mymetics Corporation, a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate will enter a new preclinical trial to confirm excellent results obtained in a previous trial.

30 Sep 2014

Johnson & Johnson inks definitive deal to acquire Alios BioPharma

Johnson & Johnson today announced a definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash.

30 Sep 2014

Researchers explain why people with asthma have hard time dealing with respiratory viruses

People with asthma often have a hard time dealing with respiratory viruses such as the flu or the common cold, and researchers have struggled to explain why.

10 Sep 2014

Cepheid releases Xpert Flu/RSV XC for accurate determination of Flu A, Flu B and RSV infection

Cepheid announced today the release of Xpert® Flu/RSV XC, an on-demand molecular test for rapid, accurate and reliable determination of Flu A, Flu B, and differentiation of RSV infection.

2 Sep 2014

New treatment fights respiratory syncytial virus

The New England Journal of Medicine published research results on Aug. 21 from a clinical trial of a drug shown to safely reduce the viral load and clinical illness of healthy adult volunteers intranasally infected with respiratory syncytial virus (RSV).

29 Aug 2014